Lynx1 Capital Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Lynx1 Capital Management’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-702,415	Closed	-$2.84M	–	17
2023 Q4	$2.84M	Hold	702,415	–	–	1.12%	11
2023 Q3	$1.89M	Sell	702,415 -54,594	-7%	-$214K	1.25%	14
2023 Q2	$7.06M	Sell	757,009 -4,249	-0.6%	-$41.9K	4.63%	8
2023 Q1	$6.76M	Sell	761,258 -22,900	-3%	-$225K	5.64%	7
2022 Q4	$3.91M	Buy	784,158 +279,296	+55%	+$1.64M	3.38%	10
2022 Q3	$2.93M	Hold	504,862	–	–	2.64%	11
2022 Q2	$2.79M	Buy	504,862 +148,035	+41%	+$1.22M	2.38%	10
2022 Q1	$4.11M	Sell	356,827 -52,531	-13%	-$562K	3.82%	9
2021 Q4	$5.19M	Buy	+409,358	New	+$6.18M	4.53%	7

Lynx1 Capital Management's THRX Position: Q1 2024 in Review

Lynx1 Capital Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 702,415 shares — an estimated $2.84M sold.

Lynx1 Capital Management first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $7.06M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Lynx1 Capital Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Lynx1 Capital Management sold 702,415 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $2.84M.
Lynx1 Capital Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Lynx1 Capital Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $7.06M in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Lynx1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.